Vanguard Asset Management’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.52M Buy
372,654
+105,532
+40% +$844K ﹤0.01% 1255
2026
Q2
$2.34M Buy
267,122
+26,065
+11% +$197K ﹤0.01% 1486
2026
Q1
$1.85M Buy
+241,057
New +$1.65M ﹤0.01% 1504

Other funds holding IBRX

Vanguard Asset Management's IBRX Position: Q3 2026 in Review

Vanguard Asset Management increased its ImmunityBio (IBRX) stake by 40% in Q3 2026, buying an estimated $844K and bringing the position to 372,654 shares worth $3.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Vanguard Asset Management first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Vanguard Asset Management held 372,654 shares of ImmunityBio worth $3.52M as of Q3 2026.
  • Vanguard Asset Management bought 105,532 ImmunityBio shares in Q3 2026, an estimated $844K.
  • ImmunityBio made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1255 holding.
  • Vanguard Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.